Trials of more selective second- and third-generation FLT3 inhibitors in adults with relapsed/refractory AML have established safety and tolerability of TKI monotherapy and in combination with chemotherapy, as well as exciting potential efficacy (14). This evidence concerns the gene FLT3 and acute myeloid leukemia.